Determination of l-(+)-bornesitol, the hypotensive constituent of Hancornia speciosa, in rat plasma by LC-MS/MS and its application on a pharmacokinetic study

Moreira, Luciana N.; Feltrin, Clarissa; Gonçalves, José Eduardo; Castro, Whocely Victor de; Simões, C. M. O.; Pádua, Rodrigo Maia de; Côrtes, Steyner F.; Braga, Fernão Castro

doi:10.1016/j.biopha.2020.110900

Cited by 9 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four sample-solvent ratios (1 : 15, 1 : 25, 1 : 35 and 1 : 60, w/v) were compared, and the sample-solvent ratio of 1 : 25 was chosen. Different ultrasonication times (15,30,40,45 and 60 min) were also compared. The results displayed that the extraction efficiency would no longer increase when the time of extraction was higher than 40 min.…”

Section: Optimization Of the Extraction Proceduresmentioning

confidence: 99%

“…14 In recent years, high-performance liquid chromatography coupled with mass spectrometry (HPLC-MS/MS) has been routinely used to determine the contents of chemical compounds in traditional chemical materials and also applied in pharmacokinetic studies in rats and humans. 15,16 Moreover, it has been used to study drug metabolism, [17][18][19][20][21][22] toxicokinetics, 23,24 lipidomics, 25,26 proteomics 27,28 and metabolomics. 29,30 The main advantage of mass spectrometry (MS/MS) is the ability to detect a broad range of drugs with high sensitivity and specicity in a single analytical run.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The development and validation of a sensitive HPLC-MS/MS method for the quantitative and pharmacokinetic study of the seven components of Buddleja lindleyana Fort.

Zhang

et al. 2021

RSC Adv.

View full text Add to dashboard Cite

show abstract

Section: Optimization Of the Extraction Proceduresmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The development and validation of a sensitive HPLC-MS/MS method for the quantitative and pharmacokinetic study of the seven components of Buddleja lindleyana Fort.

Zhang

et al. 2021

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…The l—( +)—bornesitol is the main constituent of H. speciosa leaves extract (Endringer et al 2014 ) and is a potent inhibitor of the angiotensin-converting enzyme (Moreira et al 2020 ). Therefore, it is associated with an antihypertensive effect on the species (Moreira et al 2019 ).…”

Section: Discussionmentioning

confidence: 99%

Pharmaceutical, food potential, and molecular data of Hancornia speciosa Gomes: a systematic review

Nunes

Silva-Mann

Souza

et al. 2022

Genet Resour Crop Evol

View full text Add to dashboard Cite

Hancornia speciosa Gomes is a fruit and medicinal tree species native to South America, which in Brazil is considered of potential economic value and priority for research and development. We present a map of the state-of-art, including articles, patents, and molecular data of the species to identify perspectives for future research. The annual scientific production, intellectual, social, and conceptual structure were evaluated, along with the number of patent deposits, components of the plant used, countries of deposit, international classification and assignees, and the accessibility of available molecular data. Brazil has the most significant publications (306) between 1992 and 2020. Technological products (29) have been developed from different tissues of the plant. Most of the articles and patents were developed by researchers from public universities from different regions of Brazil. The molecular data are sequences of nucleotides (164) and proteins (236) of the chloroplast genome and are described to identify the species as DNA barcodes and proteins involved in photosynthesis. The compilation and report of scientific, technological, and molecular information in the present review allowed the identification of new perspectives of research to be developed based on the gaps in knowledge regarding the species and perspectives for the definition of future research. Supplementary Information The online version contains supplementary material available at 10.1007/s10722-021-01319-w.

show abstract

“…We have demonstrated the antihypertensive properties of H. speciosa leaves by in vitro, ex vivo, and in vivo assays (Serra et al 2005;Ferreira et al 2007aFerreira et al , 2007bSilva et al 2011Silva et al , 2016Endringer et al 2014;Moreira et al 2019), and these results led to a standardized extract enriched in cyclitols and flavonoids, which is intended to be developed as an herbal medicine to treat hypertension (Braga et al 2009). The cyclitol l-( +)-bornesitol ( 7) is the main hypotensive constituent of the standardized extract (Pereira et al 2012;Moreira et al 2019), and it presents favorable pharmacokinetics in rats (Moreira et al 2020). The leaves of "mangaba" are a renewable source for exploitation, containing high amounts of bornesitol, which was the first cyclitol described as a new class of angiotensin-converting enzyme (ACE) inhibitors (Endringer et al 2014).…”

Section: Adopting Principles Of Circular Economymentioning

confidence: 99%

Paving New Roads Towards Biodiversity-Based Drug Development in Brazil: Lessons from the Past and Future Perspectives

Braga

2021

Rev. Bras. Farmacogn.

View full text Add to dashboard Cite

Although Brazil gathers two fundamental features to occupy a leading position on the development of biodiversity-based medicines, the largest flora on earth and a broad tradition on the use of medicinal plants, the number of products derived from the national genetic heritage is so far modest, either as single drugs or as herbal medicines. This article highlights some aspects that may have contributed to the low rates of success and proposes new insights for innovation. We initially approach the use of medicinal plants in Brazil, molded by its ethnic diversity, and the development of the local pharmaceutical industry. A discussion of some governmental initiatives to support plant-based drug development is then presented. Employing the economic concept of "middle-income trap," we further propose that Brazil is stuck in a "middle-level science trap," since the increase in the number of scientific publications that launched the country to an intermediate publishing position has not been translated into drug development. Two new approaches to escape from this trap are presented, which may result in innovative drug development. The first is based on the exploitation of the antifragility properties of herbal products aiming to investigate non-canonical pharmacodynamics mechanisms of action, aligned with the concepts of system biology. The second is the manufacture of herbal products based on the circular economy principles, including the use of byproducts for the development of new therapeutical agents. The adoption of these strategies may result in innovative phytomedicines, with global competitiveness.

show abstract

Determination of l-(+)-bornesitol, the hypotensive constituent of Hancornia speciosa, in rat plasma by LC-MS/MS and its application on a pharmacokinetic study

Cited by 9 publications

References 31 publications

The development and validation of a sensitive HPLC-MS/MS method for the quantitative and pharmacokinetic study of the seven components of Buddleja lindleyana Fort.

The development and validation of a sensitive HPLC-MS/MS method for the quantitative and pharmacokinetic study of the seven components of Buddleja lindleyana Fort.

Pharmaceutical, food potential, and molecular data of Hancornia speciosa Gomes: a systematic review

Paving New Roads Towards Biodiversity-Based Drug Development in Brazil: Lessons from the Past and Future Perspectives

Contact Info

Product

Resources

About